Staging Cardiac Damage in Patients With Asymptomatic Aortic Valve Stenosis.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
30 07 2019
Historique:
received: 12 02 2019
revised: 11 04 2019
accepted: 12 04 2019
entrez: 27 7 2019
pubmed: 28 7 2019
medline: 22 5 2020
Statut: ppublish

Résumé

The optimal timing of intervention in patients with asymptomatic severe aortic stenosis (AS) remains controversial. This multicenter study sought to test and validate the prognostic value of the staging of cardiac damage in patients with asymptomatic moderate to severe AS. This study retrospectively analyzed the clinical, Doppler echocardiographic, and outcome data that were prospectively collected in 735 asymptomatic patients (71 ± 14 years of age; 60% men) with at least moderate AS (aortic valve area <1.5 cm At baseline, 89 (12%) patients were classified in Stage 0, 200 (27%) in Stage 1, 341 (46%) in Stage 2, and 105 (14%) in Stage 3 or 4. Median follow-up was 2.6 years (interquartile range: 1.1 to 5.2 years). There was a stepwise increase in mortality rates according to staging: 13% in Stage 0, 25% in Stage 1, 44% in Stage 2, and 58% in Stages 3 to 4 (p < 0.0001). The staging was significantly associated with excess mortality in multivariable analysis adjusted for aortic valve replacement as a time-dependent variable (hazard ratio: 1.31 per each increase in stage; 95% CI: 1.06 to 1.61; p = 0.01), and showed incremental value to several clinical variables (net reclassification index = 0.34; p = 0.003). The new staging system characterizing the extra-aortic valve cardiac damage provides incremental prognostic value in patients with asymptomatic moderate to severe AS. This staging classification may be helpful to identify asymptomatic AS patients who may benefit from elective aortic valve replacement.

Sections du résumé

BACKGROUND
The optimal timing of intervention in patients with asymptomatic severe aortic stenosis (AS) remains controversial.
OBJECTIVES
This multicenter study sought to test and validate the prognostic value of the staging of cardiac damage in patients with asymptomatic moderate to severe AS.
METHODS
This study retrospectively analyzed the clinical, Doppler echocardiographic, and outcome data that were prospectively collected in 735 asymptomatic patients (71 ± 14 years of age; 60% men) with at least moderate AS (aortic valve area <1.5 cm
RESULTS
At baseline, 89 (12%) patients were classified in Stage 0, 200 (27%) in Stage 1, 341 (46%) in Stage 2, and 105 (14%) in Stage 3 or 4. Median follow-up was 2.6 years (interquartile range: 1.1 to 5.2 years). There was a stepwise increase in mortality rates according to staging: 13% in Stage 0, 25% in Stage 1, 44% in Stage 2, and 58% in Stages 3 to 4 (p < 0.0001). The staging was significantly associated with excess mortality in multivariable analysis adjusted for aortic valve replacement as a time-dependent variable (hazard ratio: 1.31 per each increase in stage; 95% CI: 1.06 to 1.61; p = 0.01), and showed incremental value to several clinical variables (net reclassification index = 0.34; p = 0.003).
CONCLUSIONS
The new staging system characterizing the extra-aortic valve cardiac damage provides incremental prognostic value in patients with asymptomatic moderate to severe AS. This staging classification may be helpful to identify asymptomatic AS patients who may benefit from elective aortic valve replacement.

Identifiants

pubmed: 31345430
pii: S0735-1097(19)35365-3
doi: 10.1016/j.jacc.2019.04.065
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

550-563

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Lionel Tastet (L)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Christophe Tribouilloy (C)

Department of Cardiology, Amiens University Hospital Center, Amiens, France.

Sylvestre Maréchaux (S)

Department of Cardiology, GCS-Hospital Group of the Catholic Institute of Lille, Catholic University of Lille, Lille, France.

E Mara Vollema (EM)

Department of Cardiology, Heart and Lung Center, Leiden University Medical Center, Leiden, the Netherlands.

Victoria Delgado (V)

Department of Cardiology, Heart and Lung Center, Leiden University Medical Center, Leiden, the Netherlands.

Erwan Salaun (E)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Mylène Shen (M)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Romain Capoulade (R)

Thoracic Institute, French National Institute of Health and Medical Research (INSERM), French National Center for Scientific Research (CNRS), University Hospital Center of Nantes, University of Nantes, Nantes, France.

Marie-Annick Clavel (MA)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Marie Arsenault (M)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Élisabeth Bédard (É)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Mathieu Bernier (M)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Jonathan Beaudoin (J)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Jagat Narula (J)

Department of Cardiology, Mount Sinai Hospital, New York, New York.

Patrizio Lancellotti (P)

Department of Cardiology, GIGA Cardiovascular Sciences, Cardio-Oncology Clinic, University of Liège Hospital, Sart Tilman University Hospital Center, Liège, Belgium.

Jeroen J Bax (JJ)

Department of Cardiology, Heart and Lung Center, Leiden University Medical Center, Leiden, the Netherlands.

Philippe Généreux (P)

Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; Department of Cardiology, Sacré-Coeur Hospital of Montréal, Montréal, Québec, Canada.

Philippe Pibarot (P)

Québec Heart and Lung Institute, Laval University, Québec City, Québec, Canada. Electronic address: philippe.pibarot@med.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH